Loading…
Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial
The major prognostic relevance of primary tumour location (LPT) in advanced colorectal cancer was shown in large retrospective studies, but quantitative estimates are highly heterogeneous, and there is still limited information about its impact within the framework of biomarker-guided treatment stra...
Saved in:
| Published in: | European journal of cancer (1990) 2018-09, Vol.101, p.105-113 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c384t-695d867b142a0476fed5229c2c4001a6976aeb6a26f9d6ced0f694d201ca62283 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c384t-695d867b142a0476fed5229c2c4001a6976aeb6a26f9d6ced0f694d201ca62283 |
| container_end_page | 113 |
| container_issue | |
| container_start_page | 105 |
| container_title | European journal of cancer (1990) |
| container_volume | 101 |
| creator | Hegewisch-Becker, Susanna Nöpel-Dünnebacke, Stefanie Hinke, Axel Graeven, Ullrich Reinacher-Schick, Anke Hertel, Jan Lerchenmüller, Christian A. Killing, Birgitta Depenbusch, Reinhard Al-Batran, Salah-Eddin Lange, Thoralf Dietrich, Georg Tannapfel, Andrea Arnold, Dirk |
| description | The major prognostic relevance of primary tumour location (LPT) in advanced colorectal cancer was shown in large retrospective studies, but quantitative estimates are highly heterogeneous, and there is still limited information about its impact within the framework of biomarker-guided treatment strategies. Therefore, we analysed LPT in relation to other clinical and molecular parameters, based on mature survival data from the recent randomised AIO KRK0207 trial.
Patients uniformly received first-line induction treatment with a combination of bevacizumab, oxaliplatin and fluoropyrimidine. LPT was retrospectively determined using surgical reports, pathology reports and endoscopy reports. The prognostic analyses were performed using Kaplan–Meier estimations and log-rank tests, while hazard ratios (HRs) and multivariable results were derived from Cox models.
Among 754 patients with unequivocal information on LPT, patients with left-sided tumours showed a median overall survival of 24.8 months compared with the right-sided cohort with 18.4 months (HR: 1.54, 95% confidence interval: 1.30–1.81, P |
| doi_str_mv | 10.1016/j.ejca.2018.06.015 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2075546610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804918309092</els_id><sourcerecordid>2117376547</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-695d867b142a0476fed5229c2c4001a6976aeb6a26f9d6ced0f694d201ca62283</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhiMEoqXwBzggS1y4ZDvOh5MgLktFYdVKRQucrVlnsvUqthfbKR8_nRMOuyDEgZO_nnlnPPNm2VMOCw5cnO8WtFO4KIC3CxAL4PW97JS3TZdDWxf3s1Po6i5voepOskch7ACgaSt4mJ2UAKVoyu40-7Eye1SRuYHtvTbov7E4GTd5NjqFUTvL0PZsvfxw_nq9vGRmir9ucWQh7abAtGWGIs4nrZhyo_OkYnpXaBV5Fj1hpJ590fGWDdqHmI_aEvO01YZsSCE2orbabpn7iqPej0npkHZDd6j098ng5iV7793WujBnGVLJzgc2eGdYvCW2XN2wq_UVFND8nWPWMEk7kp2LmVGP-_RFr3F8nD0YcAz05LieZZ8u33y8eJdf37xdXSyvc1W2VcxFV_etaDa8KhCqRgzU10XRqUJVABxF1wikjcBCDF0vFPUwiK7q01QUiqJoy7PsxUF3793niUKURgdF44iW3BRkqrmuKyE4JPT5P-gujSI1O1GcN2Uj6qpJVHGglHcheBrkcXSSg5ydIXdydoacnSFByOSMFPTsKD1tDPV_Qn5bIQGvDgClXtxp8jIoTalrvZ4HKnun_6f_E5WtzqI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2117376547</pqid></control><display><type>article</type><title>Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Hegewisch-Becker, Susanna ; Nöpel-Dünnebacke, Stefanie ; Hinke, Axel ; Graeven, Ullrich ; Reinacher-Schick, Anke ; Hertel, Jan ; Lerchenmüller, Christian A. ; Killing, Birgitta ; Depenbusch, Reinhard ; Al-Batran, Salah-Eddin ; Lange, Thoralf ; Dietrich, Georg ; Tannapfel, Andrea ; Arnold, Dirk</creator><creatorcontrib>Hegewisch-Becker, Susanna ; Nöpel-Dünnebacke, Stefanie ; Hinke, Axel ; Graeven, Ullrich ; Reinacher-Schick, Anke ; Hertel, Jan ; Lerchenmüller, Christian A. ; Killing, Birgitta ; Depenbusch, Reinhard ; Al-Batran, Salah-Eddin ; Lange, Thoralf ; Dietrich, Georg ; Tannapfel, Andrea ; Arnold, Dirk</creatorcontrib><description>The major prognostic relevance of primary tumour location (LPT) in advanced colorectal cancer was shown in large retrospective studies, but quantitative estimates are highly heterogeneous, and there is still limited information about its impact within the framework of biomarker-guided treatment strategies. Therefore, we analysed LPT in relation to other clinical and molecular parameters, based on mature survival data from the recent randomised AIO KRK0207 trial.
Patients uniformly received first-line induction treatment with a combination of bevacizumab, oxaliplatin and fluoropyrimidine. LPT was retrospectively determined using surgical reports, pathology reports and endoscopy reports. The prognostic analyses were performed using Kaplan–Meier estimations and log-rank tests, while hazard ratios (HRs) and multivariable results were derived from Cox models.
Among 754 patients with unequivocal information on LPT, patients with left-sided tumours showed a median overall survival of 24.8 months compared with the right-sided cohort with 18.4 months (HR: 1.54, 95% confidence interval: 1.30–1.81, P < 0.0001). In a multivariable model, LPT proved to be the strongest prognosticator (HR 1.60), with performance status, number of metastatic sites, baseline carcinoembryonic antigen (CEA) and platelets independently retaining prognostic significance. In the subgroup of patients with known RAS/BRAF status (n = 567, 75%), a BRAF mutation showed the greatest unfavourable impact (HR 3.16). Although BRAF is strongly correlated to LPT, the latter remained a significant prognosticator in the BRAF wild-type subgroup. In contrast, no major impact of LPT was seen on tumours carrying RAS mutations.
Within the framework of a uniform treatment strategy according to the current standards, LPT proved to have an important, although not solely dominating, relevance for survival prognosis. Its impact seems to be low in tumours with a RAS mutation.
ClinicalTrials.govNCT00973609.
•Primary tumour location was a major prognostic factor in patients receiving triple combinations including bevacizumab.•A right-sided tumour location retained its unfavourable prognostic impact on survival in multivariable analysis.•Performance status, number of metastatic sites, baseline CEA and platelets were additional factors of independent impact.•When incorporating molecular data, right-sided tumours were also associated with shorter survival in the BRAF-mutant subgroup.•In contrast, no prognostic impact of the location of the primary tumour could be shown in case of RAS mutations.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2018.06.015</identifier><identifier>PMID: 30036739</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bevacizumab ; Bevacizumab - administration & dosage ; Biomarkers ; BRAF mutation ; Cancer ; Cancer therapies ; Carcinoembryonic antigen ; Colon - drug effects ; Colon - metabolism ; Colon - pathology ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - genetics ; Confidence intervals ; Endoscopy ; Female ; First-line therapy ; Humans ; Immunotherapy ; Kaplan-Meier Estimate ; Maintenance Chemotherapy ; Male ; Medical treatment ; Metastases ; Middle Aged ; Monoclonal antibodies ; Mutation ; Overall survival ; Oxaliplatin ; Oxaliplatin - administration & dosage ; Patients ; Platelets ; Primary tumour location ; Prognosis ; Prognostic factors ; Proto-Oncogene Proteins B-raf - genetics ; Rank tests ; RAS mutation ; ras Proteins - genetics ; Rectum - drug effects ; Rectum - metabolism ; Rectum - pathology ; Retrospective Studies ; Subgroups ; Surgery ; Survival ; Targeted cancer therapy ; Tumors ; Young Adult</subject><ispartof>European journal of cancer (1990), 2018-09, Vol.101, p.105-113</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Sep 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-695d867b142a0476fed5229c2c4001a6976aeb6a26f9d6ced0f694d201ca62283</citedby><cites>FETCH-LOGICAL-c384t-695d867b142a0476fed5229c2c4001a6976aeb6a26f9d6ced0f694d201ca62283</cites><orcidid>0000-0002-6037-8836</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30036739$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hegewisch-Becker, Susanna</creatorcontrib><creatorcontrib>Nöpel-Dünnebacke, Stefanie</creatorcontrib><creatorcontrib>Hinke, Axel</creatorcontrib><creatorcontrib>Graeven, Ullrich</creatorcontrib><creatorcontrib>Reinacher-Schick, Anke</creatorcontrib><creatorcontrib>Hertel, Jan</creatorcontrib><creatorcontrib>Lerchenmüller, Christian A.</creatorcontrib><creatorcontrib>Killing, Birgitta</creatorcontrib><creatorcontrib>Depenbusch, Reinhard</creatorcontrib><creatorcontrib>Al-Batran, Salah-Eddin</creatorcontrib><creatorcontrib>Lange, Thoralf</creatorcontrib><creatorcontrib>Dietrich, Georg</creatorcontrib><creatorcontrib>Tannapfel, Andrea</creatorcontrib><creatorcontrib>Arnold, Dirk</creatorcontrib><title>Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>The major prognostic relevance of primary tumour location (LPT) in advanced colorectal cancer was shown in large retrospective studies, but quantitative estimates are highly heterogeneous, and there is still limited information about its impact within the framework of biomarker-guided treatment strategies. Therefore, we analysed LPT in relation to other clinical and molecular parameters, based on mature survival data from the recent randomised AIO KRK0207 trial.
Patients uniformly received first-line induction treatment with a combination of bevacizumab, oxaliplatin and fluoropyrimidine. LPT was retrospectively determined using surgical reports, pathology reports and endoscopy reports. The prognostic analyses were performed using Kaplan–Meier estimations and log-rank tests, while hazard ratios (HRs) and multivariable results were derived from Cox models.
Among 754 patients with unequivocal information on LPT, patients with left-sided tumours showed a median overall survival of 24.8 months compared with the right-sided cohort with 18.4 months (HR: 1.54, 95% confidence interval: 1.30–1.81, P < 0.0001). In a multivariable model, LPT proved to be the strongest prognosticator (HR 1.60), with performance status, number of metastatic sites, baseline carcinoembryonic antigen (CEA) and platelets independently retaining prognostic significance. In the subgroup of patients with known RAS/BRAF status (n = 567, 75%), a BRAF mutation showed the greatest unfavourable impact (HR 3.16). Although BRAF is strongly correlated to LPT, the latter remained a significant prognosticator in the BRAF wild-type subgroup. In contrast, no major impact of LPT was seen on tumours carrying RAS mutations.
Within the framework of a uniform treatment strategy according to the current standards, LPT proved to have an important, although not solely dominating, relevance for survival prognosis. Its impact seems to be low in tumours with a RAS mutation.
ClinicalTrials.govNCT00973609.
•Primary tumour location was a major prognostic factor in patients receiving triple combinations including bevacizumab.•A right-sided tumour location retained its unfavourable prognostic impact on survival in multivariable analysis.•Performance status, number of metastatic sites, baseline CEA and platelets were additional factors of independent impact.•When incorporating molecular data, right-sided tumours were also associated with shorter survival in the BRAF-mutant subgroup.•In contrast, no prognostic impact of the location of the primary tumour could be shown in case of RAS mutations.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bevacizumab</subject><subject>Bevacizumab - administration & dosage</subject><subject>Biomarkers</subject><subject>BRAF mutation</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carcinoembryonic antigen</subject><subject>Colon - drug effects</subject><subject>Colon - metabolism</subject><subject>Colon - pathology</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Confidence intervals</subject><subject>Endoscopy</subject><subject>Female</subject><subject>First-line therapy</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Kaplan-Meier Estimate</subject><subject>Maintenance Chemotherapy</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>Overall survival</subject><subject>Oxaliplatin</subject><subject>Oxaliplatin - administration & dosage</subject><subject>Patients</subject><subject>Platelets</subject><subject>Primary tumour location</subject><subject>Prognosis</subject><subject>Prognostic factors</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Rank tests</subject><subject>RAS mutation</subject><subject>ras Proteins - genetics</subject><subject>Rectum - drug effects</subject><subject>Rectum - metabolism</subject><subject>Rectum - pathology</subject><subject>Retrospective Studies</subject><subject>Subgroups</subject><subject>Surgery</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kk1v1DAQhiMEoqXwBzggS1y4ZDvOh5MgLktFYdVKRQucrVlnsvUqthfbKR8_nRMOuyDEgZO_nnlnPPNm2VMOCw5cnO8WtFO4KIC3CxAL4PW97JS3TZdDWxf3s1Po6i5voepOskch7ACgaSt4mJ2UAKVoyu40-7Eye1SRuYHtvTbov7E4GTd5NjqFUTvL0PZsvfxw_nq9vGRmir9ucWQh7abAtGWGIs4nrZhyo_OkYnpXaBV5Fj1hpJ590fGWDdqHmI_aEvO01YZsSCE2orbabpn7iqPej0npkHZDd6j098ng5iV7793WujBnGVLJzgc2eGdYvCW2XN2wq_UVFND8nWPWMEk7kp2LmVGP-_RFr3F8nD0YcAz05LieZZ8u33y8eJdf37xdXSyvc1W2VcxFV_etaDa8KhCqRgzU10XRqUJVABxF1wikjcBCDF0vFPUwiK7q01QUiqJoy7PsxUF3793niUKURgdF44iW3BRkqrmuKyE4JPT5P-gujSI1O1GcN2Uj6qpJVHGglHcheBrkcXSSg5ydIXdydoacnSFByOSMFPTsKD1tDPV_Qn5bIQGvDgClXtxp8jIoTalrvZ4HKnun_6f_E5WtzqI</recordid><startdate>201809</startdate><enddate>201809</enddate><creator>Hegewisch-Becker, Susanna</creator><creator>Nöpel-Dünnebacke, Stefanie</creator><creator>Hinke, Axel</creator><creator>Graeven, Ullrich</creator><creator>Reinacher-Schick, Anke</creator><creator>Hertel, Jan</creator><creator>Lerchenmüller, Christian A.</creator><creator>Killing, Birgitta</creator><creator>Depenbusch, Reinhard</creator><creator>Al-Batran, Salah-Eddin</creator><creator>Lange, Thoralf</creator><creator>Dietrich, Georg</creator><creator>Tannapfel, Andrea</creator><creator>Arnold, Dirk</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6037-8836</orcidid></search><sort><creationdate>201809</creationdate><title>Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial</title><author>Hegewisch-Becker, Susanna ; Nöpel-Dünnebacke, Stefanie ; Hinke, Axel ; Graeven, Ullrich ; Reinacher-Schick, Anke ; Hertel, Jan ; Lerchenmüller, Christian A. ; Killing, Birgitta ; Depenbusch, Reinhard ; Al-Batran, Salah-Eddin ; Lange, Thoralf ; Dietrich, Georg ; Tannapfel, Andrea ; Arnold, Dirk</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-695d867b142a0476fed5229c2c4001a6976aeb6a26f9d6ced0f694d201ca62283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bevacizumab</topic><topic>Bevacizumab - administration & dosage</topic><topic>Biomarkers</topic><topic>BRAF mutation</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carcinoembryonic antigen</topic><topic>Colon - drug effects</topic><topic>Colon - metabolism</topic><topic>Colon - pathology</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Confidence intervals</topic><topic>Endoscopy</topic><topic>Female</topic><topic>First-line therapy</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Kaplan-Meier Estimate</topic><topic>Maintenance Chemotherapy</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>Overall survival</topic><topic>Oxaliplatin</topic><topic>Oxaliplatin - administration & dosage</topic><topic>Patients</topic><topic>Platelets</topic><topic>Primary tumour location</topic><topic>Prognosis</topic><topic>Prognostic factors</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Rank tests</topic><topic>RAS mutation</topic><topic>ras Proteins - genetics</topic><topic>Rectum - drug effects</topic><topic>Rectum - metabolism</topic><topic>Rectum - pathology</topic><topic>Retrospective Studies</topic><topic>Subgroups</topic><topic>Surgery</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hegewisch-Becker, Susanna</creatorcontrib><creatorcontrib>Nöpel-Dünnebacke, Stefanie</creatorcontrib><creatorcontrib>Hinke, Axel</creatorcontrib><creatorcontrib>Graeven, Ullrich</creatorcontrib><creatorcontrib>Reinacher-Schick, Anke</creatorcontrib><creatorcontrib>Hertel, Jan</creatorcontrib><creatorcontrib>Lerchenmüller, Christian A.</creatorcontrib><creatorcontrib>Killing, Birgitta</creatorcontrib><creatorcontrib>Depenbusch, Reinhard</creatorcontrib><creatorcontrib>Al-Batran, Salah-Eddin</creatorcontrib><creatorcontrib>Lange, Thoralf</creatorcontrib><creatorcontrib>Dietrich, Georg</creatorcontrib><creatorcontrib>Tannapfel, Andrea</creatorcontrib><creatorcontrib>Arnold, Dirk</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hegewisch-Becker, Susanna</au><au>Nöpel-Dünnebacke, Stefanie</au><au>Hinke, Axel</au><au>Graeven, Ullrich</au><au>Reinacher-Schick, Anke</au><au>Hertel, Jan</au><au>Lerchenmüller, Christian A.</au><au>Killing, Birgitta</au><au>Depenbusch, Reinhard</au><au>Al-Batran, Salah-Eddin</au><au>Lange, Thoralf</au><au>Dietrich, Georg</au><au>Tannapfel, Andrea</au><au>Arnold, Dirk</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2018-09</date><risdate>2018</risdate><volume>101</volume><spage>105</spage><epage>113</epage><pages>105-113</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>The major prognostic relevance of primary tumour location (LPT) in advanced colorectal cancer was shown in large retrospective studies, but quantitative estimates are highly heterogeneous, and there is still limited information about its impact within the framework of biomarker-guided treatment strategies. Therefore, we analysed LPT in relation to other clinical and molecular parameters, based on mature survival data from the recent randomised AIO KRK0207 trial.
Patients uniformly received first-line induction treatment with a combination of bevacizumab, oxaliplatin and fluoropyrimidine. LPT was retrospectively determined using surgical reports, pathology reports and endoscopy reports. The prognostic analyses were performed using Kaplan–Meier estimations and log-rank tests, while hazard ratios (HRs) and multivariable results were derived from Cox models.
Among 754 patients with unequivocal information on LPT, patients with left-sided tumours showed a median overall survival of 24.8 months compared with the right-sided cohort with 18.4 months (HR: 1.54, 95% confidence interval: 1.30–1.81, P < 0.0001). In a multivariable model, LPT proved to be the strongest prognosticator (HR 1.60), with performance status, number of metastatic sites, baseline carcinoembryonic antigen (CEA) and platelets independently retaining prognostic significance. In the subgroup of patients with known RAS/BRAF status (n = 567, 75%), a BRAF mutation showed the greatest unfavourable impact (HR 3.16). Although BRAF is strongly correlated to LPT, the latter remained a significant prognosticator in the BRAF wild-type subgroup. In contrast, no major impact of LPT was seen on tumours carrying RAS mutations.
Within the framework of a uniform treatment strategy according to the current standards, LPT proved to have an important, although not solely dominating, relevance for survival prognosis. Its impact seems to be low in tumours with a RAS mutation.
ClinicalTrials.govNCT00973609.
•Primary tumour location was a major prognostic factor in patients receiving triple combinations including bevacizumab.•A right-sided tumour location retained its unfavourable prognostic impact on survival in multivariable analysis.•Performance status, number of metastatic sites, baseline CEA and platelets were additional factors of independent impact.•When incorporating molecular data, right-sided tumours were also associated with shorter survival in the BRAF-mutant subgroup.•In contrast, no prognostic impact of the location of the primary tumour could be shown in case of RAS mutations.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30036739</pmid><doi>10.1016/j.ejca.2018.06.015</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6037-8836</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2018-09, Vol.101, p.105-113 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2075546610 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Bevacizumab - administration & dosage Biomarkers BRAF mutation Cancer Cancer therapies Carcinoembryonic antigen Colon - drug effects Colon - metabolism Colon - pathology Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Confidence intervals Endoscopy Female First-line therapy Humans Immunotherapy Kaplan-Meier Estimate Maintenance Chemotherapy Male Medical treatment Metastases Middle Aged Monoclonal antibodies Mutation Overall survival Oxaliplatin Oxaliplatin - administration & dosage Patients Platelets Primary tumour location Prognosis Prognostic factors Proto-Oncogene Proteins B-raf - genetics Rank tests RAS mutation ras Proteins - genetics Rectum - drug effects Rectum - metabolism Rectum - pathology Retrospective Studies Subgroups Surgery Survival Targeted cancer therapy Tumors Young Adult |
| title | Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A02%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20primary%20tumour%20location%20and%20RAS/BRAF%20mutational%20status%20in%20metastatic%20colorectal%20cancer%20treated%20with%20first-line%20regimens%20containing%20oxaliplatin%20and%20bevacizumab:%20Prognostic%20factors%20from%20the%20AIO%20KRK0207%20first-line%20and%20maintenance%20therapy%20trial&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Hegewisch-Becker,%20Susanna&rft.date=2018-09&rft.volume=101&rft.spage=105&rft.epage=113&rft.pages=105-113&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2018.06.015&rft_dat=%3Cproquest_cross%3E2117376547%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c384t-695d867b142a0476fed5229c2c4001a6976aeb6a26f9d6ced0f694d201ca62283%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2117376547&rft_id=info:pmid/30036739&rfr_iscdi=true |